TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01234025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
Study: NCT02190604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose
Study: NCT00914511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil 200mg
Description: single dose tablet of 200mg avanafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil 200mg
Description: single tablet dose of 200mg avanafil
Study: NCT00190294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIFEPRISTONE 200 mg and misoprostol 400 µg
Description: MIFEPRISTONE 200 mg and misoprostol 400 µg
Study: NCT00814502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem CR
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Study: NCT03874507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality/Augmented Reality Headset
Description: A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view.
Study: NCT04420559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Injection
Description: Intramuscular Benzathine Penicillin Injection Procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Injection
Description: Intramuscular Benzathine Penicillin Injection Procedure
Study: NCT02161809

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Eating and Physical Activity
Description: The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
Study: NCT03734874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin
Description: 500 mg hesperidin as two capsuls

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study: NCT00752206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib
Description: Oral Agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Agent
Study: NCT03465215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital holographic microscopy
Description: Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
Study: NCT00859313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT03496597

Intervention type: PROCEDURE
Intervention: Retinal imaging assessment
Description: * OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus

Intervention type: PROCEDURE
Intervention: Retinal imaging assessment
Description: * OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus

Intervention type: PROCEDURE
Intervention: Retinal imaging assessment
Description: * OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus

Intervention type: PROCEDURE
Intervention: blood glucose holter
Description: for 40 subjects, implantation of a blood glucose holter monitor for 7 days
Study: NCT02311764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered weekly
Study: NCT04830358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuPCV15
Description: 15-valent Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: 13-valent Pneumococcal conjugate vaccine
Study: NCT03965741

Intervention type: DRUG
Intervention: Apixaban(Eliquis)
Description: Follow clinical administration

Intervention type: DRUG
Intervention: Pradaxa (Dabigatran etexilate)
Description: Follow clinical administration
Study: NCT05658588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
Study: NCT01096693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urocortin 2, Urocortin 3
Description: After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3.
Study: NCT01234025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
Study: NCT01096693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study: NCT04340544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
Study: NCT04340544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04013620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept 250 Milligram Intravenous Powder for Solution
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Study: NCT02031263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial thermoplasty system
Description: Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
Study: NCT02124694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HTUG
Description: HTUG is a group psychotherapy...
Study: NCT03157804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)
Study: NCT03257839

Intervention type: DEVICE
Intervention: Routine Full-Field Digital Mammography
Description: Routine screening mammography exam, CC + MLO views.

Intervention type: DEVICE
Intervention: Routine Digital Breast Tomosynthesis
Description: Routine screening tomosynthesis exam, CC + MLO views.

Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Bilateral breast ultrasound performed as an adjunct to mammography.
Study: NCT02301117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Study: NCT02391363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment
Description: Anxiety management skills with the option to included religious/spiritual beliefs and practices

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and referral
Description: Resource counseling and follow-up for mental health and basic needs
Study: NCT02312297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study: NCT00910780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: via oral tablets, everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: via oral tablets, everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa
Description: via oral tablets, taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal
Description: via oral tablets, taken once daily
Study: NCT03988309

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cxbladder
Description: The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care.
Study: NCT04304378

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization Techniques (ST)
Description: The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilization Techniques with Behavioral Activation (ST+BA)
Description: The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
Study: NCT02744885

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crave Crush
Description: Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
Study: NCT00748670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixture MicroThread (Micro-Macro)
Description: Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
Study: NCT02756676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Rehabilitation Treatment (MIRT)
Description: MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
Study: NCT02693041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Study: NCT01702103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Study: NCT03514667

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nanomicielle curcumin
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study: NCT00230009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Study: NCT01404702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg/m2/dose given iv on day 0 of every 28 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle
Study: NCT04050722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Repair and Protect
Description: Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection
Description: Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
Study: NCT01368549

Intervention type: OTHER
Intervention: Metanx® (a medical food)
Description: Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
Study: NCT03918187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .